Tag Archives: Inc.

Sensory Acumen, Inc. to Debut Olfactory Game Peripheral Device, GameSkunk, at GDC 2011

August 09, 2012     No comments

Orinda, CA (PRWEB) March 2, 2011

Sensory Acumen, Inc., a company engaged in the development and deployment of technologies that will enhance the consumer experience in emerging areas like mobility and interactive media, today announced the debut of a game peripheral device, GameSkunk?, which delivers a scent based on game play at the Game Developers Conference (GDC) 2011 in San Francisco, CA. Targeted at all genres of games, including family, hard core, serious, action, cooking and others, it is based on the premise that scent is emotional and is either immersive or evokes memory.

This device has dual purposes; because scent is emotional, emotions are felt with fun and serious game play. Mental researchers, psychologists, and training experts use serious games for virtual reality treatment of Post Traumatic Stress Disorder, autism, stroke, attention-deficit disorder, Alzheimer?s disease as well as combat training exercises. ?Scent is a key sensory stimulus that provides input to areas of the brain that have been implicated as relevant for both memory and emotion. Thus, better scent delivery systems could enhance the user experience and immersive properties of serious games and virtual reality simulations that have been found to be useful in both clinical practice and research,? said Albert ?Skip? Rizzo, Ph.D., associate director – Institute for Creative Technologies, University of Southern California. The evolution of computer gaming, computer simulated training, and interactive programming technologies have created an infrastructure wherein olfactory feedback systems are economically and technically feasible.

During the Game Developers Conference, Sensory Acumen will demonstrate the device and some of the scents from an evolving scent library in booth number 736. The library includes specialized clinical scents, but is not limited to the clinical market as scent is universal and though someone may experience a scent in special circumstances, every day life also experiences some of those same scents and more.

The many genres of games have one thing in common. The gamer is engrossed in an activity and activities are related to senses, e.g. touch of the controller, see the visual, hearing the soundtrack, and you can?t taste it yet, but you can smell it. ?We provide code for engines that will allow game developers to integrate the functionality of GameSkunk and its scent library into educational, training, sports, adventure, simulation, strategy, and other game genres,? says Founder & CEO Charlene Coleman, as technology allows users to become more engaged, we will see more add-ons for an immersive game play experience.

Recently, Sensory Acumen was selected to be an exhibitor at the Consumer Electronics Show (CES) Tweetup on Friday, January 7, 2011. Tech Cocktail worked with CEA on the innovation showcase of the top innovative companies at CES 2011. During the Tweetup, exhibitors presented and demonstrated their products to the 600 attendees, while attendees tweeted. The company?s twitter account is http://twitter.com/sensoryacumen. Other social media links are on Facebook, the company page http://www.facebook.com/pages/Sensory-Acumen-Inc/113718208647651 and our PTSD support page http://www.facebook.com/group.php?gid=334042096428.

About Sensory Acumen, Inc.

Sensory Acumen, Inc. is a California based privately held corporation engaged in the development and deployment of disruptive technologies that will enhance the consumer experience in emerging areas like mobility and interactive media. Sensory Acumen was founded on electrical engineering expertise with members having past experience in consumer electronics. Our mission is to deliver exceptional experiences to the end user, emerge as the leading developer of next generation technological innovations for consumer devices based on a sustainable business model, leverage a passion for delivering the experience, and leverage existing technological innovations to deliver mash-up capabilities that provide seamless processes. We provide engaging consumer electronics and related services to the end user as well as OEM to related product manufacturers. The company is a member of the Clearwire WiMAX Developer Program. http://www.sensoryacumen.com

? 2011 Sensory Acumen, Inc. GameSkunk is a trademark of Sensory Acumen, Inc.

# # #







More Attention Deficit Disorder Press Releases

Read More

Global Bipolar Disorders Market to Reach $5.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

August 03, 2012     No comments

San Jose, California (Vocus) June 11, 2010

Bipolar disorder is a chronic and devastating psychiatric disease. Since neither curable nor effectively treatable, the bipolar disorder market is present with significant unmet medical needs. The major drawbacks of existing products include dyskinesis, obsessive-compulsive behavior and psychiatric side effects, as well as ineffectiveness in treating cognitive deficits, rapid recycling or depressive symptoms. In addition, though anti-convulsants (such as Valproic acid) and lithium have considerably enhanced disease prognosis, several patients show poor tolerance to treatment-related side effects. Other major clinical setbacks include lack of compliance to treatment regimen, inadequate clinical response, and relapse.

The United States dominates the world bipolar disorder market as stated by the new market research report on bipolar disorder market. According to the U.S. National Institute of Mental Health, there are about 5.7 million adults aged 18 years and over, suffering from bipolar disorder in the US. The treatment of bipolar disorder differs based on physician specialty in the country. Most psychiatrists follow the recommendations of the American Psychological Association and prescribe lithium, valproic acid and atypical antipsychotics as first-line monotherapies for bipolar mania, and Lamictal as the recommended treatment for bipolar depression. And, unlike the psychiatrists who follow the APA guidelines and prescribe Lamictal first-line, primary care physicians select antidepressants first line.

Bipolar disorder is highly consolidated marketplace with the leading five players accounting for the lion?s share of the market. These players are unlikely to face any major challenge(s) in the future, as pipeline molecules are all targeted at providing only symptomatic relief, and no company is developing any therapy that promises a paradigm shift in the treatment of bipolar disorder. Key players profiled in the report include Abbott Laboratories Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica Inc., Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Repligen Corporation, and Validus Pharmaceuticals Inc.

The report titled ?Bipolar Disorders: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a review of unmet medical needs, opportunities and challenges, patent expiries, competitive scenario, select leading products, select pipeline drugs, clinical trials, product approvals/launches, recent industry activity, and coverage on major global market participants. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, Asia-Pacific and Rest of World. Global market is analyzed by the following drug classes – Atypical Anti-psychotics and Other Therapeutics.

For more details about this market research report, please visit ?

http://www.strategyr.com/Bipolar_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press(at)StrategyR(dot)com

Web Site http://www.StrategyR.com/

###







Read More

Medical Marketing Service Inc. Shares Successful Email Marketing Methods That Boost Open Rates by 500% and ROI by 400% at Two Leading Industry Events

August 02, 2012     No comments


Wood Dale, Illinois (PRWEB) July 27, 2012

Medical Marketing Service, Inc. (MMS) recently shared its insights regarding successful email marketing methods that can increase open rates by 500% and ROI by 400% at two leading industry conferences.

EPHARMA WEST

In the wake of the momentous Supreme Court decision affirming the Affordable Care Act, about 100 digital pharma executives gathered for the 3rd Annual ePharma West Summit, which was held July 17-19 in San Francisco.

Email marketing was on the agenda. A presentation by Terry Nugent, EVP Sales and Marketing at MMS, Inc., educated attendees about successful email marketing methods. Nugent outlined what to look for in an email ?messenger?, defined as companies such as MMS that deploy emails, and how to prepare your message so that it succeeds in its objectives. Nugent emphasized the importance of planning, including establishing quantifiable benchmarks that define success, and analyzed the top 10 and bottom 10 pharma marketing emails deployed by MMS in the past 12 months, identifying the characteristics of the successful deployments vs. the unsuccessful. To request a briefing on what it takes to create a top 10 email, contact Terry Nugent at t-nugent(at)mmslists(dot)com or 1.630.477.1553.

Other Summit sessions addressed a wide range of topics from the implications of the Supreme Court health care decision to the impact of segmentation on ROI. For an excellent summary of the proceedings blogged by James Ellis of CloserLook, go to https://workflowy.com/shared/ceb379d8-247f-0b6a-db5c-d33207e3c1d5/#/d6585882-0446-393b-3768-e65f1c4f9bca.

DIGITAL PHARMA WEST

Nugent also spoke at Digital Pharma West, during which the health reform decision news broke. Over 200 digital pharma marketers attended.

Tweets related to email marketing noted the following points:

Think about as designed vs. as rendered. Your beautiful HTML image probably will not viewable to most recipients.

You have to take the time to complete A/B testing before you send email out to all and to test on all devices.

Know your download time of images. Is an HCP going to wait for the image load in their email or delete?

Understand your target list and the types of emails will allow you to understand how the program will succeed.

Webinar emails to HCPs do very well.

Re-email to the segment that is performing best.

Open rate varies based on type of program by specialty.

Email is designed to capture attention at point a, inform and deliver the recipient to point b.

Just in time emailing works — email conference attendees with your key events the night before along with presentations.

Here is a summary of conference highlights, as indicated by the Tweeters at the meeting.

1. Supporting the Physician/Patient Relationship: Leveraging the Digital Platform to Enhance the Opportunity for Dialogue.

The event began with Pre-Conference Workshops, including an excellent seminar entitled ?Supporting the Physician/Patient Relationship: Leveraging the Digital Platform to Enhance the Opportunity for Dialogue.? Co-presenters Scott Tyson of Janssen and Beth Bengston of Hale Advisors gave a masterful overview of how to use digital media strategically. What emerged was a vision of ?Pharma 3.0? in which mobile devices are used to passively monitor patients, feed data into the electronic health record (EHR), trigger healthcare provider (HCP) interventions based on vital signs, and perhaps even adjust health insurance premiums based on therapeutic regimen and lifestyle compliance.

Those tweeting about the presentation noted 94% of EU physicians use smartphones, representing a great email opportunity!

2. Chairperson?s Opening Remarks

In the Chairperson?s opening remarks on Tuesday, June 26th, Sean O?Hagan of Daichi Sankyo cited the following statistics which were noted in tweets:

80% of US Physicians owned smartphones in 2011.

90% use digital resources during the work day

60% of physicians use digital resources during patient consultations;

There has been a 25% drop in sales reps since 2006

42% of offices with 10 or more physicians do not allow access to pharma sales representatives, making multichannel marketing including email crucial to deliver pharma promotional and educational messages.

O?Hagan noted that in today?s world, all marketers are multichannel marketers.

3. Gathering insights from consumers cost-effectively

Lauren Pennington of Pfizer spoke on gathering insights from consumers cost-effectively, generating the following tweets from the delegates:

it is possible to create a great campaign on limited budget
Pharma isn’t facing a marketing problem, it’s facing a marketing opportunity

4. Current ROI Drivers for Multi-Channel Marketing

Janssen?s Tyson made an encore the on Tuesday on a panel answering the question ?What are the Current ROI Drivers for Multi-Channel Marketing?, hosted by Mark Bard of the Digital Care Coalition. He was joined by Kelly Meyers, CEO of Qforma, and Carla Brooks, Regulatory Affairs Senior Manager, Medimmune. Those tweeting about the panel made note of several key points:

Passion and innovation are key attributes of successful digital marketers

The ROI of individual channels is difficult to ascertain, according to Tyson of Janssen, so multichannel campaign ROI must be evaluated holistically rather than by individual tactic;

“ROI” figures are soft; too many steps in the process to directly tie to sales

Be able to explain to regulatory “Why are we doing this?” Regulatory is trying to enable but wants to know what we are trying to accomplish short, medium, long run. We do more damage when we follow the ?build it & they will come? philosophy & then don?t do anything to advance that (argues for using email to promote digital solutions) – Carla Brooks, Medimmune

ROI of medium is wrong question–It’s what you do with it-Scott Tyson, Janssen. Asking the what the ROI of email is would be like asking what the ROI of a pen is – if you use it to scribble, it?s non-existent; if you use it to write the formula for the cure for cancer, it?s astronomical.

Multichannel marketing is an ecosystem of interactions. Look at your audience as a network, not as individuals. Act on the network, not the individual node to create buzz ? Kelly Myers, Qforma

For a recap by Tyler Durbin of GSW?s iQ unit, use this link: http://www.whatsyourdigitaliq.com/current-roi-drivers-for-multi-channel-marketing-digital-pharma-west/

5. The Electronic Health Record

Rich Altus, President of PDR networks noted that approximately 400,000 physicians are using electronic health records (EHRs). About 70% of large practices are using EHRs, so the growth potential is among smaller practices. Not one EHR has more than 60,000 prescribers, according to Altus.

6. Transforming relationship marketing from brand centric to enterprise-wide

Daniel Gandor of Takeda used his musical background to craft a metaphor about orchestrating the transformation of relationship marketing from a disconcerted brand-centric cacophony to an enterprise wide, customer-centric harmonious symphony.

The Twitterati shared the following key points:

Most pharma sites and email are not optimized for mobile even though HCPs are;

Takeda?s Uloric HCP relationship marketing program has 87,000 HCPs registered;

Non personal promo is taking larger role at Takeda — email is the most cost effective tactic;

A robust engagement spectrum keeps the brand in front of the physician;

We’re about to experience a shift in marketing. From a focus on the top line to the bottom line, a shift from reach to ROI.

7. Maximizing prescriber engagement in a mobile world

Epocrates hosted a panel of physicians speaking about maximizing prescriber engagement in a mobile world. Their study on digital omnivores, which found that ?3 screen? HCPs (those that use a PC, smart phone and tablet) spend more time online than single-screen users is available at http://t.co/AWtsuzDb.

One of the most notable observations was that physicians want comparative data about brands. They would have the most respect for a marketer who listed all the brands available in a particular therapeutic class and presented data comparing their product with its competitor on the basis of safety and efficacy and perhaps even cost and thus cost-effectiveness.

Other tweetable moments included:

HCPs want 3 types of content for HCPs: 1 minute, 5 minute or lots of information

Digital omnivores will more than double by Q2 2013

8. Achieving oversize results on modest budgets

Bill Drummy of Heartbeat Digital made an outstanding presentation about achieving oversize results on modest budgets. Using a David vs. Goliath motif. Drummond showed how one of his smallest clients conducted a successful campaign that used patient insights gleaned from mobile to create a breakthrough campaign in the hemophilia market by establishing genuine rapport with sufferers, who refer to themselves as bleeders, by speaking to them in their own language.

Drummy noted that digital campaigns generate up to 29:1 ROI, and that email ROI is very good. He believes that the current opportunity presented by limited budgets will act as a catalyst for adoption of digital marketing in lieu of less cost-effective tactics.

9. Mobile marketing Opportunity in Pharma

The meeting concluded with a daylong workshop on mobile marketing in pharma. Chris Ballentine of Takeda made an excellent presentation highlighting the physician-patient nexus. According to Ballentine, 70% of patients would use an app recommended by their physician, and 9 out of 10 doctors say they want to use apps to help patients manage diseases. This represents an opportunity for pharma to assist HCPs in connecting with their patients. Envision a world in which pharma emails an app link to doctors, and doctors forward it to their patients via email or even Twitter. If such aps could help patients manage diseases less expensively, it would certainly benefit all stakeholders in healthcare: patients, HCPs, and payers. There are regulatory issues. But pharma should certainly take on this challenge to move to a Pharma 3.0 model where the product is not just a pill, it is a solution to the healthcare challenge of the 21st century – achieving better quality AND reducing cost.????

10. See for yourself

All and all, it was a very educational and informative conference. A twitter transcript of the meeting is available at http://hashtags.symplur.com/healthcare-hashtag-transcript.php?hashtag=DigPharm&fdate=06-25-2012&shour=14&smin=13&tdate=06-27-2012&thour=14&tmin=13&ssec=00&tsec=00&img=1

KEEP UP WITH MMS

MMS will be speaking at future industry events on a regular basis. To find out where and when, follow us @mmsemail

ABOUT MMS

Since 1929, Medical Marketing Service, Inc. (MMS), the industry leader in healthcare lists and email marketing, has been pinpointing perfect prospects for clients including pharmaceutical marketers, continuing medical education (CME) providers, publishers, and recruiters, along with the their list brokers, ad agencies and other marketing partners. MMS?s motto is message delivered – we deliver messages to over 1.5 million healthcare professionals (HCPs).

Service is our surname for a reason – personal service by people who care and have decades of experience is the hallmark of our heritage.

Generations of satisfied customers are our legacy, and the foundation of our future – that?s why referrals are our number one source of new customers. We look forward to helping the industry meet the challenges of the 21st century – helping the industry do more with less by achieving maximum return on investment (ROI) with gold standard lists, databases and email marketing services.

MMS was the first Database Licensee of the American Medical Association (AMA), widely recognized as the finest physician database in the world, and guaranteed 99% deliverable for direct mail by MMS. Upon that foundation we have built a selection of lists that maintain that same discerning standard of excellence to reach the entire spectrum of health professionals, featuring lists of the leading healthcare professional associations in each discipline. The results of this decades-long effort to bring you the best available lists and databases are establishment of one source you can rely on for all your healthcare list and email marketing needs.

MMS allows you to reach all the critical healthcare professionals you need to succeed with an integrated, multichannel direct marketing approach that diversifies your campaigns across all media – direct mail, telemarketing, broadcast fax, and email.

For more information, go to http://www.mmslists.com, call 1.800.MED.LIST (633.5478), email sales(at)mmslists(dot)com, and follow us on Twitter @mmsemail.







Find More Cancer Press Releases

Read More

Smart Kids With Learning Disabilities, Inc. Announces Its 2009 Youth Achievement Award Contest, A National Contest Recognizing High Achievers with Learning Disabilities

July 31, 2012     No comments

Westport, CT (PRWEB) November 11, 2008

Smart Kids with Learning Disabilities, Inc. announces its 2009 Youth Achievement Award Contest, a nationwide recognition for high achievers with learning disabilities. Students, ages 19 or younger, are eligible for the $ 1,000 award. Candidate must demonstrate initiative, talent and determination resulting in a notable accomplishment in any field, including art, music, math, athletics, or community service.

Teachers, coaches, mentors, parents or students themselves are invited to submit an application. Application forms are posted on the organization’s website. Contest deadline is January 31, 2009. Applications from Canada are also welcome.

The winner will be expected to attend the awards ceremony, to be held during the annual benefit gala on Saturday, April 25, 2009, in Fairfield County, Connecticut. Transportation and hotel accommodations will be provided for the winning student and his/her parents.

Honorable Mentions will also be awarded, though attendance will not be required.

Henry Winkler, author of the Hank Zipzer books featuring a hero with learning disabilities (LD) and attention-deficit hyperactivity disorder (ADHD), will also be honored at the event, according to Jane Ross, Executive Director of Smart Kids with Learning Disabilities, Inc.

“Henry Winkler is perhaps better known as “The Fonz,” the highly popular fictional character on Happy Days, which resulted in at least two Golden Globe Awards for best TV actor for Winkler,” said Jane Ross. “What may be less known about Henry Winkler is that he grew up struggling with dyslexia. We are proud to be honoring him during our annual benefit gala and Youth Achievement Awards presentation. We are proud to celebrate the strengths and accomplishments of both adults and students with learning disabilities and ADHD.”

Last year, the winner of the 2008 Youth Achievement Award was 19-year-old Evan Paul of Lynnfield, MA, a sophomore at the University of Arizona in Tucson and CEO of egameplace.com, a videogame-trading site he set up at age 15. He is also the co-founder of Dyslexic Dreams, a nonprofit supporting young people with dyslexia.

Honorable Mentions in 2008 were awarded to six students from Huntsville, TX, Rockville, MD, Colorado Springs, CO, Savannah, GA, Trumbull, CT and Bethesda, MD.

About Smart Kids with Learning Disabilities, Inc.:

Smart Kids with Learning Disabilities, Inc. is a non-profit organization dedicated to empowering parents of children with learning disabilities (LD) and attention-deficit disorder (ADHD). Its mission is to educate, guide and inspire families dealing with disabilities and to change the perception of learning disabilities as a stigmatizing condition. David Neeleman, founder and former chairman of JetBlue Airways, serves as the organization’s Honorary Chairman.

Contact:

Jane Ross, Executive Director

Smart Kids with Learning Disabilities, Inc.

203-226-6831

http://www.SmartKidswithLD.org

# # #







Read More

Raland Therapeutics, Inc. Announces Board of Directors

July 27, 2012     No comments

Fairport, NY (PRWEB) March 05, 2012

Raland Therapeutics, Inc. a transformational medical device company has successfully recruited and seated a highly regarded Board of Directors to guide the dynamic company forward. Represented are experts in business from the areas of science, engineering, finance, operations, sales and marketing.


Dante Pennacchia, Chairman – Current CEO of Maxualize, LLC, former VP (Sales) at Bausch & Lomb, and former CMO at Pictometry (2001 to 2010).

Dr. Bradford Berk, Director – Current CEO of University of Rochester Medical Center and visionary in the Rochester medical community.

Efrain Rivera, Director – Current CFO & Treasurer of Paychex, Inc. and former CFO of Bausch & Lomb.

Carl Yankowski, Director – Current CEO of Westerham Group, former CEO Palm Computer, former President & COO of Sony Electronics and former CEO of Reebok.

Dale Canning, Director & Secretary – Current CEO of Raland Technologies, LLC and former CEO of Premier Technical Services, Inc.

Bill Rader, Executive Director – Current President & CEO of Raland Therapeutics, Inc.and serial entrepreneur.

?We believe that we weigh the success of our company in our favor when we combine our team of business experts with our groundbreaking science and technology?, said Bill Rader, CEO of RTI. ?It is our core competency to move discoveries through the arduous process ahead in order to reach our ultimate goal which is to benefit the patient in an expeditious and cost-effective manner.?

Raland Therapeutics, Inc. (RTI) has a number of medical devices in its current pipeline including: RxFusion? , a device that allows for easier and safer infusions of multiple drug products; Cytocomm? , an implantable biosensor used to diagnose and treat many varied conditions and diseases and PlexiSense? an intravascular smart device for the treatment of a variety of medical issues ranging from Parkinson?s and epilepsy to heart conditions.

About Raland Therapeutics

Raland Therapeutics, Inc. is a company focused on interventional medicine and therapeutic devices. We transform novel ideas into innovative medical devices and treatment methods. Our experience and passion drive us to solving complex clinical problems and improving patient care. With offices located in Fairport NY, Raland has further reach through alliances with top research universities and companies located around the United States. For more information on Raland Therapeutics; visit the company’s website at http://www.ralandcorp.com

###





Related Parkinsons Press Releases

Read More

Pelmorex Media Inc. and ES3? Partner to Deliver The Weather Network/ M?t?oM?dia iTV Application for Microsoft? Mediaroom?

July 24, 2012     No comments

Toronto, Canada (PRWEB) January 19, 2012

ES3 and Pelmorex Media Inc. celebrated International CES 2012 with the announcement of the global market release of The Weather Network/ M?t?oM?dia application for Mediaroom IPTV Service Operators.

Pelmorex and ES3 have partnered to deliver what is believed to be the most compelling, personalized weather application for TV to date. The application provides TV users with localized current conditions, short-term and long-term weather information, weather warnings, and seasonal weather information such as ski, pollen and UV reports and more. Save up to nine alternative locations that could include your favourite locations of any major city in the world, in order to plan your travel and vacations in a more informed way.

As the partnership evolves, ES3 and Pelmorex will release The Weather Network widget for ES3?s TV Dashboard product and The Weather Network application for over-the-top (OTT) TV devices in 2012.

Doug Edwards, CEO of ES3 commented, ?The early, positive feedback around the release of The Weather Network?s on-channel application for Mediaroom is quite exciting for us! Our partnership with Pelmorex is important to ES3 as it addresses a significant vertical in our content-based TV application strategy. Our 2012 plans and partnering activities will unleash more compelling interactive TV experiences on ES3 application platforms and other devices, leveraging the wealth of information and innovation that Pelmorex offers as a leading Canadian brand and global partner. We?re very proud to have released a TV application in partnership with Pelmorex that truly influences users? daily lives and travel decisions!?

?As a company that?s known for innovation, Pelmorex is excited to keep pace with consumer technology by being the first licensed broadcaster to launch on the Mediaroom platform in Canada,? said Naomi Lipowski, Director iTV, Pelmorex Media Inc. ?We?re already working together with ES3 on the next feature set and are thrilled to be able to offer viewers a breadth of data and information so that they can drill down in detail, on demand and on their own time to plan for anything.?

About ES3?

ES3 is an award-winning TV application provider with a series of content, social and utility-based interactive TV applications delivered on the Microsoft Mediaroom IPTV platform for Service Operators, globally.

For media inquiries, please contact:

ES3 (Canada)

Amy Parrington

CEO’s Office/ES3 Media Relations

+ 905.839.3770 x24

email: news(at)es3(dot)ca

website: http://www.es3.ca

Pelmorex Media Inc. (Canada)

Trevor Campbell

+ 905.829.1159

email: tcampbell(at)pelmorex(dot)com

website: http://www.theweathernetwork.com

# # #





Related OM Press Releases

Read More

Global Irritable Bowel Syndrome (IBS) Therapeutics Market to Reach $1.47 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 24, 2012     No comments

(PRWEB) August 25, 2011

San Jose, California (PRWEB), August 25, 2011 — Irritable Bowel Syndrome, a recurring Gastrointestinal illness, represents an under-penetrated market with a large number of generic drugs presently in use for treating the multiple symptoms. Owing to lack of proper understanding of the disease etiology, the causes, and misdiagnosis of symptoms, only countable number of drugs is presently available in the market for treating more than one symptom associated with IBS. However, over the years, the market has witnessed several improvements, such as the establishment of well-defined diagnostic criteria, exploring novel therapeutic drug classes, emergence of alternative medicines and therapies, in addition to the growing awareness about the chronic nature of the disease.

The global market for Irritable Bowel Syndrome (IBS) therapeutics is presently underserved with a high degree of fragmentation due to the non-availability of a single drug for treating all symptoms associated with this chronic illness. Further, upon considering the diagnostic scenario, nearly 70% of the cases remain undiagnosed while the disease prevalence is quite high. During the initial onset of the disease, patients prefer self-medication based upon their symptoms and rely upon OTC products. The prescription market for IBS comprises of a very few approved drugs for addressing more than one symptom, which show only sub optimal efficacy, and in some cases result in adverse side effects. Physicians prescribe multiple drugs that are not adequate for subsiding the pain, discomfort, and other IBS symptoms. The approval and subsequent release of safe and effective medicines for IBS treatment in the near future is expected to result in substantial growth of the IBS market owing to the premium pricing of these drugs upon release.

The US represents the largest market for irritable bowel syndrome (IBS) therapeutics worldwide, as stated by the new market research report on Irritable Bowel Syndrome Therapeutics. Europe represents the second largest market for IBS therapeutics. Rest of World is projected to emerge as the fastest growing market for IBS therapeutics, exhibiting a CAGR of more than 12% over the analysis period.

The high prevalence and anticipated launch of new drugs in the developed markets during and post 2012 is expected to drive the growth of the IBS market in the coming years. Lotronex (2000) and Amitiza (2008) are the only drugs presently approved for the treatment of Diarrhea Predominant IBS (IBS-D) and Constipation Predominant IBS (IBS-C), respectively. Post US FDA approval and market release in February 2000, Lotronex was withdrawn from the US market in December 2000 owing to safety concerns over this drug. Lotronex was re-launched in 2005, although with a warning label, for restricted use in patients in whom the risk to benefit ratio is balanced. The re-launch of the drug despite the risk associated with its use reflects the high unmet need existing in the IBS therapeutics market. Amitiza, approved for the treatment of IBS-C, is associated with adverse events and side effects. The drug?s safety profile limits the drug?s market size despite its efficacy.

The late stage drug pipeline of Irritable Bowel Syndrome comprises of drug candidates with novel mechanisms of action, and do not belong to the 5HT class of drugs which dominated the drug-development pipeline for the past several years. Despite the efficacy, 5HT class of drugs lack gut-selectivity acting on receptors present in the gut as well as the brain, which is the primary reason for the side effects associated with their use. New drugs in the late stage IBS pipeline, including Linaclotide, Asimadoline, and Dexloxiglumide, exhibit novel modes of action and have demonstrated positive results in terms of safety and efficacy in their respective late stage clinical trials, which makes them promising candidates in the field of IBS treatment. Moreover, each of these is found to be effective in treating a particular IBS-subtype, and not just a single symptom associated with IBS, in respective clinical studies.

Major players profiled in the report include Abbott Laboratories, Edusa Pharmaceuticals, Ironwood Pharmaceuticals Inc., Forest Laboratories Inc., Lexicon Pharmaceuticals, Ocera Therapeutics Inc., Pharmos Corporation, Sucampo Pharmaceuticals Inc., Tioga Pharmaceuticals Inc., among others.

The research report titled ?Irritable Bowel Syndrome (IBS) Therapeutics: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the Irritable Bowel Syndrome (IBS) market, the disease prevalence, classification, causes, diagnosis, current treatment scenario, select treatments and therapies along with side effects, product approvals in the past, clinical trials, early and late stage pipeline, recent industry activity, product innovations, and profiles of major/niche global market participants. The report provides annual value sales estimates and projections for Irritable Bowel Syndrome Therapeutics market for the years 2009 through 2017 for the following geographic regions ? US, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Irritable_Bowel_Syndrome_IBS_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







More Early Onset Press Releases

Read More

FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications

July 23, 2012     No comments

(PRWEB) June 19, 2012

FirstVitals Health and Wellness, Inc., of California, in partnership with AlohaCare, Hawaii?s largest safety-net health plan, has been awarded a three year, $ 4 million CMS Innovation Challenge Grant to combine telemedicine, specialized care coordination and social media to help low-income diabetic people in Hawaii improve their health. The program, entitled ?Improving the Health and Care of Low-Income Diabetics at Reduced Costs,? will be administered to 600 select AlohaCare QUEST members with type 1 and 2 diabetes across the islands.

The program is designed around the use of cellular-enabled blood glucose meters, internet-connected tablets and proprietary home-based imaging and sensing devices to track key clinical information and facilitate easy communication with the patient to enable early detection and prevention of complications.

FirstVitals and AlohaCare will use claims and other data to identify patients who might benefit most from this program, including those with risk factors for diabetic foot disease. Clinical data collected will be transmitted wirelessly to Care Coordinators hired specifically for the project. If thresholds are exceeded, the Care Coordinator will intervene in various ways, depending on the individual circumstances, from a text message alert to the patient or a parent, video chat using the tablet, up to a home visit; all in close partnership with the patient?s primary care provider. The project will also involve social media to educate and encourage family and friends to support the patient.

Over the three-year grant period, AlohaCare and FirstVitals will analyze data on glycemic control, emergency room visits, hospitalization, medication use and other indicators to measure both the health condition of the members and overall impact on medical care expenses. AlohaCare?s care management software enables AlohaCare to track both individual progress and the overall condition and health costs of the subject group.

David Goodman, MD, MSE, FirstVitals co-founder and Program Medical Director said, ?We are honored that CMS selected the FirstVitals program to receive one of its Innovation Challenge grants. We believe that our affiliation with AlohaCare offers an ideal opportunity to demonstrate the power of innovative technology coupled with compassionate care to improve clinical outcomes while lowering costs in this very challenging population.”

?This grant will directly enhance the quality of health care for these patients, as well as provide key research for the nation?s health care system about how to use technology and focused care management in a way that works,? said John McComas, Chief Executive Officer of AlohaCare. ?It combines high-tech and high-touch, technology and personal service, to provide better care, better health and lower costs.?

FirstVitals, founded in 2010 to deliver scalable health, wellness and disease management programs based on proprietary technology-enabled services, is planning to deploy its unique diabetes intervention which, in addition to improving glycemic control, will incorporate technologies that can enable early identification of patients at risk of diabetes-related complications early enough to prevent, such as foot ulcers.

FirstVitals is planning to incorporate a foot care module into its intervention, because diabetic foot ulcers are one of the most feared and expensive diabetic complications. Diabetic foot ulcers are the leading cause of lower extremity amputations in the United States and diabetic foot problems are responsible for 20% of all costs of care related to diabetes.

AlohaCare is a non-profit community health plan serving about 80,000 members in the State of Hawaii?s MedQUEST Medicaid program. AlohaCare was in 1994 formed by the leaders of Hawaii?s community health centers and that partnership will be a critical feature in the success of implementing the innovation grant.

FirstVitals Contact: Ernie Lee

Mobile: 925-209-4450

Office: 925-743-0102

e-mail: ernie.lee(at)firstvitals(dot)com

AlohaCare Contact: Daryl Huff

Office: (808) 973-1569

Mobile: (808) 722-9806

e-mail: dhuff(at)alohacare(dot)org







Read More

Global ADME-Toxicology Testing Market to Exceed $10 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 21, 2012     No comments

San Jose, California (PRWEB) August 29, 2011

New drug discovery is increasingly becoming a high cost proposition for pharmaceutical and biotech companies, owing particularly to the high attrition rate due to drug failure at different stages. Development of a new drug costs about $ 1.0 billion and takes, on an average, 7-10 years before reaching commercialization stage. With companies facing major revenue losses owing to patent expirations and demanding regulatory requirements, besides growing cost pressures, there is growing need to reduce fixed costs and adopt flexible cost models. ADME-Tox issues comprise a leading cause for drug failure/attrition during the pre-clinical as well as clinical stage. The increasing number of drug targets and volume of assay points in drug discovery process are necessitating the need for identifying and eliminating potential hits with high ADME and toxicity profiles. Hence ADME/Tox screening has now become essential at early stage drug discovery and development process. In addition, rising drug discovery costs are fostering the adoption of extensive ADME-Tox screenings not only at early stage of drug discovery and development process but also through the entire process.

Pharma companies are focusing efforts on various innovative approaches to enhance and accelerate ADME-Tox assessments. In silico predictive ADME-Tox is growing at a fast clip and is expected to gain further momentum as the technology can drastically reduce the expenditure incurred due to late stage failure of drug compounds owing to poor ADME-Tox properties. The use of computational models in prediction of ADME/Toxicity properties of compounds is also increasing at a rapid rate owing to the fact that these models offer significant benefits in high throughput screening (HTS). Owing to the significant role of transporter proteins, analysis of drug transporters is gradually becoming a part of ADME assessment and is likely to become a part of regulatory standard for new drug applications.

The United States and Europe account for a lion?s share of the global ADME-Toxicology testing market, as stated by the new market research report on ADME-Toxicology Testing. With the US being home to most of the global pharmaceutical giants, the nation corners a major share of new drug discoveries across the world. The US market for In-Vivo Toxicology testing is forecast to exceed US$ 1.0 billion by 2015. Cell-based assays are expected to emerge as a vital technology in in-vitro test methods in toxicity testing, given their role either as a part of a tiered testing scheme or as test batteries in predicting human toxicity endpoints. Growing interest in screening new drug candidates has propelled the manufacturers of cell-based assays to provide reliable and robust solutions for drug discovery. High Throughput/High Content (HTS/HCS) cell-based assays enable the evaluation of several toxicity endpoints, which is expected to enable identification of various aspects associated with the onset of cell stress. This, in turn, aids in predicting specific cytotoxic effects.

While the US is expected to continue its dominant position in global market, developing regions including Asia-Pacific are poised to register the fastest growth. The high growth in these markets is buoyed by government support and increasing number of collaborations between foreign pharma companies and research laboratories in the region. In particular, India and China have rapidly emerged as ?hot spot? for R&D investment. The emergence and success of contract research organizations (CROs) has made outsourcing of various research projects related to new drug development a viable alternative for pharmaceutical companies, particularly for mid-tier and small players with inadequate infrastructure. Increasing emphasis on early stage ADME-Tox screening and prediction during the last decade and a half has resulted in emergence of large number of dedicated ADME-Tox CROs.

ADME-Tox technologies market place includes pharmaceutical and biotech companies with their in-house research teams and contract research organizations (CROs) that provide ADME-Tox screening at contract. Select players profiled in the report include Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd, CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cyprotex PLC, Entelos, Inc., Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., Optivia Biotechnology, Inc., Promega Corporation, Taconic Farms, Inc., Thermo Fisher Scientific, Inc., Xceleron, Inc. among others.

The research report titled ?ADME-Toxicology Testing: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a strategic review of the drug discovery and development market, key market trends in ADME-Tox Technologies, recent product launches, strategic corporate initiatives, and profiles of key market participants. The report provides annual expenditure on ADME-Tox Technologies by the following geographic markets – US, Canada, Japan, Europe and Rest of World. Segments analyzed include Toxicology (In-Vivo and In-Vitro) and ADME.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/ADME_Toxicology_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Read More

R.E.A.D. Inc. Celebrates 35-Year Anniversary with Summer Session

July 21, 2012     No comments


San Leandro, CA (Vocus/PRWEB) May 27, 2011

San Leandro?s R.E.A.D. Inc., an independent after school tutoring center, celebrates its 35th anniversary by offering a summer program to help children retain and improve their academic skills that otherwise would get rusty over the summer break.

R.E.A.D., located in San Leandro, by the fire station and library, offers year-round after school tutoring and summer programs. R.E.A.D.’s summer program is the perfect opportunity for children to catch up, master fundamentals or get ahead in the six week session.

?R.E.A.D. is proud to have been in business for 35 years serving the East Bay from its San Leandro center,? said Lori Diestel, director of R.E.A.D., Inc. “We focus on each child’s needs and work cooperatively with their teachers and parents.”

R.E.A.D.?s summer program consists of a six-week session designed for a child?s specific needs. Enrollment is open until June 7 with instruction starting on June 27. Attending READ?s summer program can help children avoid the loss of critical skills during summer vacation while enjoying learning activities for a few hours each week. The program is designed to improve children?s academic skills, focusing on subject areas such as reading comprehension, spelling, writing, phonics, math, algebra, geometry, trigonometry, biology, and chemistry. It is also great preparation for expected fall coursework. The program will also reinforce children?s organizational and time management skills.

About R.E.A.D. Inc.

R.E.A.D. is a tutoring service covering elementary school through high school subjects. They have been working with children and their parents since 1975. R.E.A.D. has programs designed to assist students who are experiencing academic difficulties in school due to learning disabilities, attention deficit disorders or poor organizational and study skills. They work in small groups with two to three students per teacher. They operate in the San Leandro area and in the Tri-Valley area of Dublin, Pleasanton, and San Ramon.

# # #







Read More
« Older posts
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv